The Impact on Clinical Practice of Routine Screening for Macroprolactin [PDF]
Obstetrical & Gynecological Survey, 2005 Macroprolactin has reduced bioactivity in vivo and accumulates in the sera of some subjects, resulting in pseudo-hyperprolactinemia and consequent misdiagnosis.We have audited our experience of routine screening for macroprolactin using polyethylene glycol (PEG) precipitation over a 5-yr period in a single center.Application of a reference range for ...
J, Gibney, T P, Smith, T J, McKenna
openaire +3 more sources
Diagnosis of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM) [PDF]
Archives of Endocrinology and MetabolismHyperprolactinemia is a frequent cause of menstrual irregularity, galactorrhea, hypogonadism, and infertility. The most common etiologies of hyperprolactinemia can be classified as physiological, pharmacological, and pathological.
Andrea Glezer +9 more
doaj +2 more sources
Evaluation of Macroprolactin Levels in Females with Hyperprolactinemia
Annals of Pathology and Laboratory MedicineBackground: Macroprolactinemia is defined as hyperprolactinemia due to high levels of macroprolactin. The term 'macroprolactinemia' is used when the levels of macroprolactin exceed 60% of the total serum prolactin concentration estimated by polyethylene ...
Premjeet Kaur Bhuee, A. Birdi
semanticscholar +2 more sources
Macroprolactinemia in a Patient with Invasive Macroprolactinoma: A Case Report and Minireview [PDF]
Case Reports in Endocrinology, 2013 Background. Macroprolactin, the high-molecular prolactin isoform, is considered to be an inactive in vivo product with extrapituitary origin. Patients with macroprolactinemia are usually asymptomatic, with negative pituitary imaging. Based on these data,
Atanaska Elenkova +5 more
doaj +2 more sources
Final recommendations for macroprolactin
Pathology, 2023 L. Boscato +4 more
semanticscholar +2 more sources
Mild hyperprolactinemia in women with polycystic ovary syndrome. Insights from a large cross-sectional study [PDF]
Journal of Clinical & Translational EndocrinologyBackground: Hyperprolactinemia is an exclusion criterion for polycystic ovary syndrome (PCOS), albeit PCOS itself is argued to induce mild hyperprolactinemia.
Manuel Luque-Ramírez +6 more
doaj +2 more sources
Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis. [PDF]
Case Rep MedSemaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is widely used for weight management and glycemic control. While its metabolic and gastrointestinal effects are well characterized, its potential influence on pituitary function remains underexplored.
Guimarães GNF.
europepmc +2 more sources
Response of Macroprolactinemia to Dopamine Agonists
Endocrinology Research and Practice, 2008 Macroprolactinemia, defined as hyperprolactinemia with a predominance of the big big prolactin (macroprolactin) isoform, is considered idiopathic and poorly symptomatic. Although macroprolactinemia has been considered to be a cause of apparent resistance
Gonca Tamer +3 more
doaj +3 more sources
Kaohsiung Journal of Medical Sciences, 2012 This study investigated the differences in clinical and laboratory features as well as treatment response in 70 outpatients with macroprolactinemia and monomeric hyperprolactinemia treated with dopamine agonists.
Chih-Chin Lu, Ching-Jung Hsieh
doaj +3 more sources
PLoS ONE, 2013 Clinical trials evaluating the rate of short-term selective serotonin-reuptake inhibitor (SSRI)-induced hyperprolactinemia have produced conflicting results.
Sollip Kim, Young-Min Park
doaj +2 more sources